In 1979, the FDA approved the name brand drug Reglan for the gastrointestinal disorders gastroesophageal reflux disease or GERD, and gastroparesis. It wasn't long after that the drug, which was meant to be used for short-term use of no longer than 3 months, started to show serious health risks. Patients taking the drug soon started to show symptoms of tardive dyskinesia, a neurological disorder signified by involuntary and repetitive body movements. Though TD was discovered in the 1950s, it's believed that Reglan and metoclopramide was a leading cause of the long-term disorder since distribution. In February of 2009, the FDA issued its strongest warning against metoclopramide.